Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019   Launch Commenced of VASCEPA ® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb.
View HTML
Toggle Summary Amarin to Present at Two Upcoming Investor Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at two upcoming investor conferences. Mr.
View HTML
Toggle Summary Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2019 financial results and provide an
View HTML
Toggle Summary Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today that BioNJ awarded Amarin with an Innovator Award in recognition of the approval of a new indication for VASCEPA® (icosapent ethyl) by the U.S.
View HTML
Toggle Summary Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk
Recent survey of healthcare professionals reveals need for more education and dialogue on scientific advances and regulatory actions to ensure optimal cardiovascular health care DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today
View HTML
Toggle Summary Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook
Unaudited Full-Year 2019 Net Total Revenue Estimated At or Slightly Above Upper-End of Prior Guidance of $410 to $425 Million U.S. Sales Force Expansion On-Track for Doubling to 800 Sales Professionals in Early 2020 Full-Year 2020 Net Total Revenue Guidance Reiterated at $650 to $700 Million, 
View HTML
Toggle Summary Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on
View HTML
Toggle Summary VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events
VASCEPA becomes the first and only Health Canada approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatment Commercial launch expected in mid-February 2020 by Amarin’s commercial partner for Canada VASCEPA
View HTML
Toggle Summary Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
VASCEPA becomes the first and only FDA-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment Millions of people in the United States qualify as treatment candidates for VASCEPA Cardiovascular disease events, including
View HTML
Toggle Summary European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA)
View HTML

Amarin Corporation